

The information in the press release is intended for investors.

Isofol participates in the ESMO cancer congress

GOTHENBURG, Sweden, October 16, 2025 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISO FOL) announces today that the company will participate in the ESMO (European Society for Medical Oncology) cancer congress in Berlin, October 17–21. An abstract describing the study design for Isofol's ongoing clinical phase Ib/II study with arfolitixorin has been accepted for presentation at the congress.

Isofol is developing arfolitixorin – a proprietary clinical-stage drug candidate designed to enhance the efficacy of established cancer treatments. Based on extensive clinical research, arfolitixorin is now being tested in a phase Ib/II clinical study with an optimized dose regimen, conducted at the renowned German university hospital Charité – Universitätsmedizin Berlin. The drug candidate has the potential to fill a known treatment gap in cancer care.

At the annual ESMO cancer congress, an abstract describing the design of Isofol's ongoing clinical phase Ib/II study will be presented as an ePoster. The abstract is a so-called TiP (Trial in Progress) abstract, covering the study design and recruitment status. The study evaluates a new dose regimen and escalating doses of arfolitixorin in combination with 5-FU chemotherapy as well as oxaliplatin and bevacizumab as first-line treatment in patients with metastatic colorectal cancer (mCRC).

Isofol's abstract is available here: [Posters and ePosters – ESMO Congress 2025](#)

"We are very excited to participate in ESMO – one of the world's most important scientific meetings in oncology. Being part of this context is important for Isofol as it allows us to contribute to scientific progress, while also strengthening our network as well as the confidence in and visibility of arfolitixorin," says Roger Tell, Chief Medical Officer at Isofol.

In connection with the participation at ESMO, Isofol will conduct a site visit at Charité and discuss the progress of the study together with the study's coordinating investigator, Prof. Dr. med. Sebastian Stintzing. The ongoing study is conducted within the framework of a collaboration agreement, signed in May 2024, between Isofol and Charité covering strategic planning and the further clinical development of arfolitixorin.

Colorectal cancer is the third most common form of cancer globally, and the second most common cause of cancer-related death, according to the World Health Organization. The need for new treatments in the field is therefore high.

For more information, please contact

Isofol Medical AB (publ)

Petter Segelman Lindqvist, Chief Executive Officer

E-mail: petter.s.lindqvist@isofolmedical.com

Phone: +46 (0) 739 60 12 56

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on October 16, 2025.

About Isofol

Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofofmedical.com